Prelude Therapeutics (PRLD)
Prelude Therapeutics Statistics
Share Statistics
Prelude Therapeutics has 55.15M shares outstanding. The number of shares has increased by 0.41% in one year.
Shares Outstanding | 55.15M |
Shares Change (YoY) | 0.41% |
Shares Change (QoQ) | 0.22% |
Owned by Institutions (%) | 42.4% |
Shares Floating | 34.37M |
Failed to Deliver (FTD) Shares | 75 |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 3.12M, so 5.66% of the outstanding shares have been sold short.
Short Interest | 3.12M |
Short % of Shares Out | 5.66% |
Short % of Float | 11.03% |
Short Ratio (days to cover) | 4.53 |
Valuation Ratios
The PE ratio is -0.76 and the forward PE ratio is -0.76. Prelude Therapeutics's PEG ratio is 0.04.
PE Ratio | -0.76 |
Forward PE | -0.76 |
PS Ratio | 13.75 |
Forward PS | 0.4 |
PB Ratio | 0.73 |
P/FCF Ratio | -0.93 |
PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Prelude Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.3, with a Debt / Equity ratio of 0.14.
Current Ratio | 5.3 |
Quick Ratio | 5.3 |
Debt / Equity | 0.14 |
Debt / EBITDA | -0.13 |
Debt / FCF | -0.17 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $53.44K |
Profits Per Employee | $-970.79K |
Employee Count | 131 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.26% in the last 52 weeks. The beta is 1.42, so Prelude Therapeutics's price volatility has been higher than the market average.
Beta | 1.42 |
52-Week Price Change | -83.26% |
50-Day Moving Average | 0.88 |
200-Day Moving Average | 2.38 |
Relative Strength Index (RSI) | 51.76 |
Average Volume (20 Days) | 238.85K |
Income Statement
In the last 12 months, Prelude Therapeutics had revenue of 7M and earned -127.17M in profits. Earnings per share was -1.68.
Revenue | 7M |
Gross Profit | 7M |
Operating Income | -139.71M |
Net Income | -127.17M |
EBITDA | -139.71M |
EBIT | -139.71M |
Earnings Per Share (EPS) | -1.68 |
Balance Sheet
The company has 12.47M in cash and 18.02M in debt, giving a net cash position of -5.55M.
Cash & Cash Equivalents | 12.47M |
Total Debt | 18.02M |
Net Cash | -5.55M |
Retained Earnings | -583.56M |
Total Assets | 175.51M |
Working Capital | 110.25M |
Cash Flow
In the last 12 months, operating cash flow was -102.89M and capital expenditures -764K, giving a free cash flow of -103.65M.
Operating Cash Flow | -102.89M |
Capital Expenditures | -764K |
Free Cash Flow | -103.65M |
FCF Per Share | -1.37 |
Margins
Gross margin is 100%, with operating and profit margins of -1995.91% and -1816.76%.
Gross Margin | 100% |
Operating Margin | -1995.91% |
Pretax Margin | -1816.76% |
Profit Margin | -1816.76% |
EBITDA Margin | -1995.91% |
EBIT Margin | -1995.91% |
FCF Margin | -1480.74% |
Dividends & Yields
PRLD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for PRLD is $4, which is 406.3% higher than the current price. The consensus rating is "Buy".
Price Target | $4 |
Price Target Difference | 406.3% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | -5.91 |
Piotroski F-Score | 3 |